Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05074485 · ClinicalTrials.gov registry record · Phase 1
Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience
A Phase 1 study of Pain, sponsored by Alan Prossin.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05074485: Recruiting Phase 1 study of Pain, sponsored by Alan Prossin.
NCT05074485 is a Phase 1 study of Pain that is actively recruiting participants, run by Alan Prossin. The registered enrollment target is 70 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05074485, a Phase 1 study of Pain, is actively recruiting participants, sponsored by Alan Prossin.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The first objective of the study is to evaluate whether a novel bio-signature (derived from a wide range of pro- and anti-nociceptive IL-1 family cytokine activity) will predict pain experienced and also release of underlying endogenous opioid neurotransmitters during an experimental nociceptive pain challenge, which will be performed while simultaneously quantifying mu-opioid receptor activity in the brain via \[11C\]-carfentanil PET neuroimaging in healthy subjects. Another objective is to evaluate whether an anti-inflammatory drug that reduces activation of IL-1b (minocycline) will perturb the balance between pro- and anti-nociceptive IL-1 cytokines and effect a reduction in pain experienced (and endogenous opioids released) during the experimental, nociceptive pain challenge. A final objective is to evaluate performance characteristics (sensitivity, accuracy, dynamic range) of the biosignature for the purpose of predicting post-operative pain.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG anakinra
- OTHER Nociceptive pain challenge
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-07-19 |
| Est. Completion | 2026-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05074485
The ClinicalTrials.gov registry entry for NCT05074485 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (77% lower). The listed sponsor is Alan Prossin, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05074485 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05074485 about?
NCT05074485 is a clinical study titled "Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience". The first objective of the study is to evaluate whether a novel bio-signature (derived from a wide range of pro- and anti-nociceptive IL-1 family cytokine activity) will predict pain experienced and also release of underlying endogenous opioid neurotransmitters during an experimental nociceptive pai...
What is the current status of trial NCT05074485?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2021-07-19. Estimated completion is 2026-05-07.
What conditions does trial NCT05074485 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT05074485?
The interventions under investigation include: Placebo (DRUG), anakinra (DRUG), Nociceptive pain challenge (OTHER).
Who is sponsoring clinical trial NCT05074485?
This trial is sponsored by Alan Prossin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05074485 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
RECRUITING · Phase 1
-
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
RECRUITING · Phase 1
-
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Phase 1 Study of SBS-147 in Healthy Adults
RECRUITING · Phase 1
-
Patient Controlled Administration of Liquid Acetaminophen
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.